Literature DB >> 6590827

QT interval prolongation associated with anthracycline cardiotoxicity.

K S Bender, J P Shematek, B G Leventhal, J S Kan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6590827     DOI： 10.1016/s0022-3476(84)80026-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  7 in total

Review 1.  A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?

Authors:  F A Fish; D M Roden
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

2.  Ventricular repolarization time indexes following anthracycline treatment.

Authors:  B Sarubbi; M Orditura; V Ducceschi; F De Vita; L Santangelo; F Ciaramella; G Catalano; A Iacono
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

3.  Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center.

Authors:  W P Miller; R Shanley; P Dorostkar
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

4.  Electrocardiographic abnormalities and mortality in aging survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study.

Authors:  Daniel A Mulrooney; Elsayed Z Soliman; Matthew J Ehrhardt; Lu Lu; Daniel A Duprez; Russell V Luepker; Gregory T Armstrong; Vijaya M Joshi; Daniel M Green; Deokumar Srivastava; Matthew J Krasin; G Stephen Morris; Leslie L Robison; Melissa M Hudson; Kirsten K Ness
Journal:  Am Heart J       Date:  2017-04-04       Impact factor: 4.749

5.  Heart rate and catecholamine contribution to QT interval shortening on exercise.

Authors:  P Davey; J Bateman
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

6.  Mitral regurgitation after anthracycline treatment for childhood malignancy.

Authors:  J Allen; J D Thomson; I J Lewis; J L Gibbs
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

7.  Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Authors:  C J Punt; E E Voest; E Tueni; A T Van Oosterom; A Backx; P H De Mulder; B Hecquet; C Lucas; B Gerard; H Bleiberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.